argenx SE
ARGX
#391
Rank
$65.117 B
Marketcap
Netherlands
Country
$1,047.10
Share price
21.09%
Change (1 day)
35.16%
Change (1 year)
Categories
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for…
Key Metrics
Trailing P/E
37.82
Forward P/E
28.64
EPS (TTM)
$26.29
Forward EPS
$34.72
Price / Book
184.70
EV / EBITDA
962.1x
Beta
-0.03
Dividend Yield
—
Return on Equity
23.64%
Return on Assets
11.63%
Debt / Equity
0.56
Current Ratio
5.12
Gross Margin
59.07%
Operating Margin
31.99%
Net Profit Margin
32.27%
Free Cash Flow
$761.769M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-3.73%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$4.153B
Latest Net Income$1.292B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare argenx SE with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
ARGX
No recent news available. Set FINNHUB_API_KEY to enable news.
